Description: ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
2. Incremental cost-effectiveness ratio - Wikipedia
Description: The incremental cost-effectiveness ratio (ICER) is a statistic used in cost-effectiveness analysis to summarise the cost-effectiveness of a health care intervention. It is defined by the difference in cost between two possible interventions, divided by the difference in their effect. It represents the average incremental cost associated with 1 additional unit of the measure of effect.
3. About Us | Institute for Clinical & Economic Review - ICER
Description: ICER provides an independent source of evidence review—free from financial conflicts of interest—to address these fundamental questions. By doing so, we help patients today and in the future by catalyzing a movement toward fair pricing, fair access, and future innovation across the entire US health care system.
4. What is ICER and how does it promote discriminatory drug ...
Description: The Institute for Clinical and Economic Review (ICER) produces reports, known as “cost effectiveness analyses” or “value assessments” on how much it thinks new drugs should cost. ICER metrics value treating young individuals in good health as more cost-effective than treating older adults (65 and older) or people with disabilities.
Description: The 14th annual conference will be a virtual conference due to continued challenges presented by the Covid-19 pandemic. Many details remain to be determined, but please plan to join us August 16-19, 2021 for another excellent ICER experience.
Description: ICER’s price shouldn’t disturb Novartis much—unlike the harsh exchange of words the cost watchdog prompted from Amgen and Regeneron. The two antibody drugs first came to market in 2015 ...